AI Terminal
N4 PHARMA PLC
Regulatory Filings • Feb 3, 2025
7804_rns_2025-02-03_f5e8e7f2-4052-49c5-a0f0-07038e48a507.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4945V
Ananda Pharma PLC
03 February 2025
03 February 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Ananda Pharma Appoints Viridian Capital Advisors to Advance U.S. Market Strategy
Ananda Pharma plc (AQSE: ANA), a Company focused on the development of cannabinoid-based therapies for the treatment of a range of complex conditions, today announces the appointment of Viridian Capital Advisors with immediate effect.
Viridian Capital Advisors ( https://www.viridianca.com/ ) is a leading New York and Aspen-based advisory boutique specialising in the cannabis and CBD industries, and has a strong track record in advising companies, raising capital, and facilitating strategic growth in the sector.
Commenting on the appointment, Melissa, CEO of Ananda Pharma, said:
"We are delighted to partner with Viridian Capital Advisors. Their proven track record in the cannabis sector and extensive network within the U.S. investment community will be invaluable as we build our profile in the U.S. market. The U.S. market is the largest for cannabinoid-based pharmaceuticals and offers a dynamic investment landscape well-suited to our goals."
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub:
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn : https://www.linkedin.com/company/anandapharma
· X : https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| [email protected] | |
| Chief Executive Officer | |
| Melissa Sturgess | |
| Finance Director | |
| Jeremy Sturgess-Smith | |
| SP ANGEL CORPORATE FINANCE LLP | +44 (0)20 3470 0470 |
| Corporate Finance | |
| Richard Morrison | |
| Corporate Broking | |
| Abigail Wayne | |
| Rob Rees | |
| Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 [email protected] |
About Ananda Pharma
Ananda is an AQSE-listed life sciences company focused on the research and clinical development of cannabinoid therapies for a range of complex conditions.
For more information, please visit: www.anandapharma.co.uk
https://investors.anandapharma.co.uk/link/pegVZy
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXLFLFXEFLBBBF